'Temporary headwinds' clip second quarter performance for Takeda

Tokyo-headquartered pharma major Takeda (TYO: 4502) has announced results for the first half of its fiscal year, which in Japan runs from April 1 to September 1, 2023.

Revenues hit 2.1 trillion Japanese yen ($13.1 billion) for the period, an increase of 6.4%, with the earnings per share (EPS) figure coming in at 27 yen, a fall of 75%, the decline attributable to a non-cash impairment charge booked in the second quarter.

Chief executive Christophe Weber noted that “development setbacks with Exkivity and Alofisel,” had impacted reported profit, highlighting “the inherent risk in research and development in the pharmaceutical business.”